PARIS, June 6 (Reuters) – French drugmaker Sanofi SA
and U.S. partner Regeneron Pharmaceuticals Inc
said a one-year, late-stage study of dupilumab, a
monoclonal antibody designed for the treatment…
The post Sanofi and Regeneron report positive skin disease trial appeared first on NASDAQ.